摘要
目的研究E2F-1、NF-κB/P65和P-gp在弥漫性大B细胞淋巴瘤(DLBCL)中的表达及意义。方法应用免疫组织化学SP法检测E2F-1、NF-κB/P65和P-gp在61例DLBCL和15例反应性增生淋巴结中的表达,分析E2F-1、NF-κB/P65、P-gp表达与DLBCL临床病理特征和预后的关系。结果①61例DLBCL中,E2F-1表达的阳性率为42.6%,明显低于反应性增生的淋巴结(P<0.05);NF-κB/P65和P-gp表达的阳性率分别为52.5%和54.1%,均高于淋巴结反应性增生(P<0.05)。②61例DLBCL中,E2F-1的表达与NF-κB/P65和P-gp的表达呈负相关,NF-κB/P65和P-gp的表达呈正相关。③在DLBCL中,E2F-1的表达与患者的性别、年龄、Ann Arbor分期、IPI评分、LDH值及B症状均无关(P>0.05);NF-κB/P65的表达与患者的Ann Arbor分期及IPI评分有关(P<0.05),与患者的性别、年龄、LDH值及B症状无关(P>0.05);P-gp的表达与患者的IPI评分有关(P<0.05),而与患者的性别、年龄、Ann Arbor分期、LDH值及B症状无关(P>0.05)。④E2F-1阳性表达者5年生存率明显高于E2F-1阴性表达者,差异有统计学意义(P=0.03);NF-κB/P65阳性表达者5年生存率明显低于NF-κB/P65阴性表达者,差异有统计学意义(P=0.01);P-gp阳性表达者5年生存率虽然低于P-gp阴性表达者,但差异无统计学意义(P=0.12)。结论①部分DLBCL患者存在原发性多药耐药。②在DLBCL中,E2F-1、NF-κB/P65和P-gp之间存在相关性,提示三者在弥漫性大B细胞淋巴瘤中可能存在一定的相互作用,共同参与了肿瘤耐药。③E2F-1低表达和NF-κB/P65高表达是DLBCL预后不良的指标。
Objective To investigate the expression and significance of E2F-1 ,NF-κB/P65 and P-gp in diffuse large B cell lymphoma（DLBCL）. Methods Immunohistochemical SP method was used to detect the expression of E2F-1, NF-κB/ P65 and P-gp in 61 cases of diffhse large B cell lymphoma tissue and 15 cases of reactive hyperplasia lymph nodes. Their relationship with clinicopathologic parameters and prognosis were analyzed. Results ①Among the 61 cases of DLBCL tissue, the positive rates of E2F-1 was 42.6%, which was significantly lower than that of reative hyperplasia lymph nodes （P 〈 0.05 ） ;the positive rates of NF-κB/ P65 and P-gp were 52.5% and 54.1% respectively. The rates were significantly higer than reative hyperplasia lymph nodes （P 〈 0.05 ）. ②Among the 61 cases of DLBCL tissue, the expression of E2F-1 was negatively correlated with the ex- pression of NF-κB/P65 and P-gp. The expression of NF-κB/P65 was positively correlated with expression of P-gp. ③The expres- sion of E2F-1 had no significant correlation wih gender, age, Ann Arbor stage, IPI score, LDH and B sympton （ P 〉 0.05 ） ; The ex- pression of NF-κB/ P65 was significantly correlated with Ann Arbor stage and IPI score （P 〈 0.05 ）, but not with gender, age, LDH and B sympton（ P 〉 0.05 ） ;The expression of P-gp had correlation with IPI score （P 〈 0.05 ）, but had no correlation with gender, age, Ann Arbor stage, LDH and B sympton （ P 〉 0.05 ）. ④The 5-year survival rate of the E2F-1 positive patients was sig- nificantly higher than that of E2F-1 negative patients, the difference between them was significant （P = 0.03 ） ;The 5-year survival rate of that of NF-κB/P65 positive patients was significantly lower than the NF-κB/P65 negative patients,the difference between them was significant（P = 0.01 ） ; The 5-year survival rate of the P-gp positive patients was lower than the P-gp negative patients, but the difference was not significant（P = 0.12）. Conclusion ①In DLBCL, some patients exist primar muhidrug resistance. ② In DLBCL, E2F-1, NF-κB/P65 and P-gp are correlated, which suggest that they may have a certain degree of interaction and par- ticipate in the occurrence of tumor drug resistance. ③The low expression of E2F-1 and the high expression of NF-κB/ P65 areunfavourable prognostic indicators in DLBCL.
出处
《实用癌症杂志》
2013年第2期150-154,共5页
The Practical Journal of Cancer
